CA2485545A1 - (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazol cristallin, et utilisation de ladite substance en tant que medicament antithrombotique - Google Patents

(r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazol cristallin, et utilisation de ladite substance en tant que medicament antithrombotique Download PDF

Info

Publication number
CA2485545A1
CA2485545A1 CA002485545A CA2485545A CA2485545A1 CA 2485545 A1 CA2485545 A1 CA 2485545A1 CA 002485545 A CA002485545 A CA 002485545A CA 2485545 A CA2485545 A CA 2485545A CA 2485545 A1 CA2485545 A1 CA 2485545A1
Authority
CA
Canada
Prior art keywords
methyl
ethyl
benzimidazole
amidinophenylaminomethyl
pyrrolidinocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002485545A
Other languages
English (en)
Inventor
Guenter Linz
Peter Sieger
Gunnar Schreiner
Werner Rall
Rolf Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2485545A1 publication Critical patent/CA2485545A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La présente invention concerne les formes cristallines des composés (R)-2-(4-amidinophénylaminométhyl)-1-méthyl-5-(1-(carboxyméthylamino)-1-(pyrrolidinocarbonyl)-éthyl)-benzimidazol et son monohydrochlorure, des procédés de production desdites substances et leur utilisation en tant que médicaments à action antithrombotique.
CA002485545A 2002-06-20 2003-06-16 (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazol cristallin, et utilisation de ladite substance en tant que medicament antithrombotique Abandoned CA2485545A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10227666A DE10227666A1 (de) 2002-06-20 2002-06-20 (R)-2-(4-Amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)- ethyl]-benzimidazol, dessen Monohydrochlorid, Verfahren zu deren Herstellung sowie Verwendung als Arzneimittel
DE10227666.8 2002-06-20
PCT/EP2003/006317 WO2004000818A1 (fr) 2002-06-20 2003-06-16 (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazol cristallin, et utilisation de ladite substance en tant que medicament antithrombotique

Publications (1)

Publication Number Publication Date
CA2485545A1 true CA2485545A1 (fr) 2003-12-31

Family

ID=29719306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002485545A Abandoned CA2485545A1 (fr) 2002-06-20 2003-06-16 (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazol cristallin, et utilisation de ladite substance en tant que medicament antithrombotique

Country Status (9)

Country Link
EP (1) EP1529035A1 (fr)
JP (1) JP2006508037A (fr)
AR (1) AR040445A1 (fr)
AU (1) AU2003237945A1 (fr)
CA (1) CA2485545A1 (fr)
DE (1) DE10227666A1 (fr)
TW (1) TW200413329A (fr)
UY (1) UY27856A1 (fr)
WO (1) WO2004000818A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349022B2 (en) 2010-12-21 2017-04-13 The Medicines Company (Leipzig) Gmbh Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
DE19962329A1 (de) * 1999-12-23 2001-06-28 Boehringer Ingelheim Pharma Benzimidazole, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1529035A1 (fr) 2005-05-11
DE10227666A1 (de) 2004-01-08
AR040445A1 (es) 2005-04-06
TW200413329A (en) 2004-08-01
JP2006508037A (ja) 2006-03-09
WO2004000818A1 (fr) 2003-12-31
UY27856A1 (es) 2003-12-31
AU2003237945A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
EP3121171B1 (fr) Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
US20070275995A1 (en) Thiobenzimidazole derivatives
EP2257544B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
JP4870660B2 (ja) Ｃｘｃｒ４アンタゴニストの合成プロセス
CA2550726A1 (fr) Procedes de preparation de formes cristallines d'aripiprazole
HU187773B (en) Process for preparing substituted imidazole derivatives maceutical compositions containing such compounds
AU2006319984B2 (en) Acid addition salt of optically active dihydropyridine derivative
US5387684A (en) Isoindazole compound
CA2485545A1 (fr) (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazol cristallin, et utilisation de ladite substance en tant que medicament antithrombotique
US9095585B2 (en) Bioavailable compositions of amorphous piperidinyl compounds
US7169934B2 (en) (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition
US20080076934A1 (en) (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1- (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition
US4261896A (en) 1-Substituted-2-(substituted-imino)-1H-1,2-dihydrobenz[cd]indoles
JPH11506753A (ja) 平滑筋細胞増殖の阻害薬としてのスチリルベンゾイミダゾール誘導体
US20040162311A1 (en) Benzimidazole derivative
EP0111397A1 (fr) Dérivés de l'isoindole, préparation et utilisation
US4581460A (en) Substituted 1-benzoyl-2-phenyliminoimidazolidine derivatives
JPH02124885A (ja) イミダゾール抗不整脈剤
AU675035B2 (en) Benzene derivatives and pharmaceutical composition
JP2001199983A (ja) ベンズイミダゾール誘導体
JP3269658B2 (ja) フェノール誘導体
CA2436265A1 (fr) Dihydrochlorure d'acide 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoique, et procede d'elaboration
JPH0413666A (ja) １―（アルコキシフェニル）―３―（４，５，６，７―テトラヒドロベンズイミダゾリル）ウレア
JP3618341B2 (ja) 臭化物及びその結晶
JP2798094B2 (ja) 抗菌剤としてのジクロロ置換イミダゾール誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead